CD133 turned out to be effective for identifying CSCs in carcinomas of lung [25,26,56], ovary [57], stomach [58], colon [46,59], gallbladder [60], head and neck [61], pancreas [47], and liver [36], as well as glioblastoma [62], lymphoma [45], Ewing’s sarcoma [63], and in other human neoplasms [64,65]. Here, PROM1 is linked to neoplasm.